Asset Details
Do you wish to reserve the book?
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype
Do you wish to request the book?
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype
2010
Overview
Background:
We aimed to clarify the incidence and the clinicopathological value of non-muscle myoglobin (Mb) in a large cohort of non-invasive and invasive breast cancer cases.
Methods:
Matched pairs of breast tissues from 10 patients plus 17 breast cell lines were screened by quantitative PCR for Mb mRNA. In addition, 917 invasive and 155 non-invasive breast cancer cases were analysed by immunohistochemistry for Mb expression and correlated to clinicopathological parameters and basal molecular characteristics including oestrogen receptor-α (ER
α
)/progesteron receptor (PR)/HER2, fatty acid synthase (FASN), hypoxia-inducible factor-1α (HIF-1
α
), HIF-2
α
, glucose transporter 1 (GLUT1) and carbonic anhydrase IX (CAIX). The spatial relationship of Mb and ER
α
or FASN was followed up by double immunofluorescence. Finally, the effects of estradiol treatment and FASN inhibition on Mb expression in breast cancer cells were analysed.
Results:
Myoglobin mRNA was found in a subset of breast cancer cell lines; in microdissected tumours Mb transcript was markedly upregulated. In all, 71% of tumours displayed Mb protein expression in significant correlation with a positive hormone receptor status and better prognosis.
In silico
data mining confirmed higher Mb levels in luminal-type breast cancer. Myoglobin was also correlated to FASN, HIF-2
α
and CAIX, but not to HIF-1
α
or GLUT1, suggesting hypoxia to participate in its regulation. Double immunofluorescence showed a cellular co-expression of ER
α
or FASN and Mb. In addition, Mb levels were modulated on estradiol treatment and FASN inhibition in a cell model.
Conclusion:
We conclude that in breast cancer, Mb is co-expressed with ER
α
and co-regulated by oestrogen signalling and can be considered a hallmark of luminal breast cancer phenotype. This and its possible new role in fatty acid metabolism may have fundamental implications for our understanding of Mb in solid tumours.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - pathology
/ Carcinoma, Intraductal, Noninfiltrating - metabolism
/ Female
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Neoplasms, Hormone-Dependent - metabolism
/ Oncology
/ Tumors
